Industries > Pharma > Global Diabetes Drugs Market 2017-2027

Global Diabetes Drugs Market 2017-2027

Insulin and Insulin Analogues, DPP-4 Inhibitors, Biguanides, GLP-1 Agonists, Alpha-glucosidases, SGLT-2 Inhibitors, Sulfonylureas and Others

PUBLISHED: 27 July 2017
PAGES: 262
PRODUCT CODE: PHA0218
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE
SKU: PHA0218 Categories: , Tag:

The global diabetes drugs market was valued at $49.26bn in 2016 and is projected to grow at a CAGR of 6.1% in the first half of the forecast period.to reach global revenue of $66.29bn in 2021. The largest drug class in the market in 2016 was human insulin and analogues. This drug class held 55% share of the global diabetes drugs market in 2016.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand-new 262 page report you will receive 75 tables and 141 figures – all unavailable elsewhere.

The 262-page report provides clear detailed insight into the global diabetes drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Diabetes Drugs Market forecasts from 2017-2027

• Provides qualitative analysis and forecast of the human insulins and analogues submarket for the period 2017-2027:
• Lantus (insulin aspart)
• NovoLog (insulin aspart)
• Humalog (insulin lispro)
• Levemir (insulin detemir)
• Human Insulins by Novo Nordisk
• NovoMix (insulin aspart)
• Humulin (insulin isophane)

• Provides qualitative analysis and forecast of the dipeptidyl peptidase-4 inhibitors (DPP-4) submarket for the period 2017-2027:
• Januvia (sitagliptin)
• Janumet (sitagliptin and metformin)
• Galvus (vidagliptin)
• Onglyza (saxagluiptin)
• Nesina (alogliptin)
• Tradjenta (linagliptin)

• Provides qualitative analysis and forecast of the sulfonylurea submarket for the period 2017-2027:
• Diamicron (gliclazide)
• Amaryl (glimepiride)
• Glucotrol (glipizide)

• Provides qualitative analysis and forecast of the glucagon-like peptide-1 (GLP-1) receptor agonists submarket for the period 2017-2027:
• Victoza (liraglutide)
• Byetta (exenatide)
• Bydureon (exenatide)

• Provides qualitative analysis and forecast of the alpha-glucosidase class submarket for the period 2017-2027:
• Glucobay (acarbose)
• Basen (voglibose)
• Glyset (miglitol)

Global Diabetes Drugs Market 2017-2027

• Provides qualitative analysis and forecast of the meglitinides submarket for the period 2017-2027:

• Prandin (repaglinide)
• Sarlix (nateglinide)
• Glufast (acarbose).

• Provides qualitative analysis and forecast of the sodium-glucose co-transporter 2 (SGLT2) inhibitors submarket for the period 2017-2027:
• Invokana (canagliflozin)
• Forxiga (dapagliflozin)
• Jardiance (empaglifozin)

• Provides qualitative analysis and forecast of the biguanides submarket for the period 2017-2027:
• Glucophage (metformin)
• Glumetza (metformin)
• Fortamet (metformin)

• This report provides individual revenue forecasts to 2027 for these regional and national markets:
• United States
• Japan
• EU5 (Germany, France, UK, Italy, Spain)
• China
• India
• Russia
• Brazil

• This report discusses the SWOT and STEP Analysis of the global diabetes drugs market

• This report also discusses the diabetes R&D pipeline, recent approvals and summarizes anti-diabetes drug developments by Novo Nordisk, Eli Lilly, Boehringer Ingelheim, AstraZeneca and others

Visiongain’s study is intended for anyone requiring commercial analyses for the global diabetes drugs market. You find data, trends and predictions.

Buy our report today Global Diabetes Drugs Market 2017-2027: Insulin and Insulin Analogues, DPP-4 Inhibitors, Biguanides, GLP-1 Agonists, Alpha-glucosidases, SGLT-2 Inhibitors, Sulfonylureas and Others.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

1. Report Overview
1.1 Introduction to the Diabetes Industry and Market
1.2 Main Report Findings
1.3 This Study Provides the Following Knowledge
1.4 Why You Should Read This Report
1.5 How This Report Delivers
1.6 Main Questions Answered by This Study
1.7 Who is This Study For?
1.8 Research Methods and Analysis
1.9 Frequently Asked Questions (FAQ)
1.10 Associated Visiongain Reports
1.11 About Visiongain

2. Global Diabetes Drugs Market: Introduction
2.1 Global Diabetes Drugs Market Segmentation
2.2 What is Diabetes?
2.3 How is Diabetes Classified?
2.4 Risk Factors, Disease Symptoms and Complications
2.5 Criteria for the Diagnosis of Diabetes
2.6 World and Regional Diabetes Incidence and Prevalence
2.7 The Economic Burden of Diabetes
2.8 Unmet Need
2.9 Leading Classes of Diabetic Medications
2.9.1 Type 1 Medication
2.9.1.1 Insulin
2.9.1.2 Surgical Options
2.9.2 Type 2 Medication
2.9.2.1 Alpha-glucosidase Inhibitors
2.9.2.2 Biguanides
2.9.2.3 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
2.9.2.4 Sodium-Glucose Co-Transporter 2 (SGLT2)
2.9.2.5 Thiazolidinediones
2.9.2.6 Sulfonylureas
2.9.2.7 Meglitinides
2.9.2.8 Other Injectable Medications
2.9.2.9 Combination Drug Therapies for Type 2 Diabetes

3. The World Diabetes Drugs Market, 2017-2027
3.1 The World Diabetes Drug Market, 2016
3.1.1 Diabetes Treatment Market by Drug Class, 2016
3.1.2 Top Selling Diabetes Drugs, 2016
3.1.3 Generic Anti-Diabetes Drugs, 2016
3.2 World Diabetes Drugs Market: Revenue Forecast, 2017-2027
3.3 Injectable and Non-Injectable Diabetes Drugs, 2017-2027
3.3.1 Injectable Diabetes Drugs Revenue Forecast, 2017-2027
3.3.2 Non-Injectable Diabetes Drugs Revenue Forecast, 2017-2027

4. Human Insulin and Analogues, 2017-2027
4.1 Insulin and Insulin Analogues Drugs, 2016
4.2 Insulin and Insulin Analogues: Revenue Forecast, 2017-2027
4.3 Insulin and Insulin Analogues: Market Trends, 2017-2027
4.3.1 Will the Top 3 Insulin Producers Sustain Their Market Dominance?
4.3.2 New Opportunities for Biosimilar Insulin: Is the Era of Biosimilar Insulin Coming?
4.4 Lantus (Insulin Aspart, Novo Nordisk): Revenue Forecast, 2017-2027
4.5 NovoLog (Insulin Aspart; Novo Nordisk): Revenue Forecast, 2017-2027
4.6 Humalog (Insulin Lispro; Eli Lilly): Revenue Forecast, 2017-2027
4.7 Levemir (Insulin Detemir; Novo Nordisk): Revenue Forecast, 2017-2027
4.8 Human Insulins (Novo Nordisk): Revenue Forecast, 2017-2027
4.9 NovoMix (Insulin Aspart; Novo Nordisk): Revenue Forecast, 2017-2027
4.10 Humulin (Insulin Isophane; Eli Lilly): Revenue Forecast, 2017-2027

5. Dipeptidyl Peptidase-4 Inhibitors (DPP-4) Market, 2017-2027
5.1 DPP-4 Market, 2016
5.2 DPP-4 Inhibitors Revenue Forecast, 2017-2027
5.3 Januvia (Sitagliptin; Merck (MSD)): Revenue Forecast, 2017-2027
5.4 Janumet (Sitagliptin and Metaformin; Merck & Co.): Revenue Forecast, 2017-2027
5.5 Galvus (Vildagliptin; Novartis): Revenue Forecast, 2017-2027
5.6 Onglyza (Saxagliptin; AstraZeneca): Revenue Forecast, 2017-2027
5.7 Nesina (Alogliptin; Takeda/Furiex Pharmaceuticals): Revenue Forecast, 2017-2027
5.8 Tradjenta (Linagliptin; Eli Lilly and Boehringer Ingelheim): Revenue Forecast, 2017-2027

6. Sulfonylureas Market, 2017-2027
6.1 Sulfonylureas Market, 2016
6.2 Sulfonylureas: Revenue Forecast 2017-2027
6.3 Sulfonylureas: Market Trends 2017-2027
6.3.1 New Opportunites for Sulfonylureas in Emerging Markets
6.3.2 Side Effects and Competitor Drugs Will Affect Sales
6.4 Diamicron (Gliclazide; Servier): Revenue Forecast, 2017-2027
6.5 Amaryl (Glimepiride; Sanofi): Revenue Forecast, 2017-2027
6.6 Glucotrol XL (Glipizide; Pfizer): Revenue Forecast, 2017-2027

7. Glucagon-Like Peptide-1 (GLP-1) Receptor agonists Market, 2017-2027
7.1 GLP-1 Receptor agonists Market, 2016
7.2 GLP-1 Receptor Agonists Revenue Forecast, 2017-2027
7.2.1 GLP-1 Receptor Agonists: Market Trends, 2017-2027
7.2.2 Promising New Approvals in the GLP-1 Class
7.2.3 GLP-1 Agonists and Weight Loss Results May Boost Revenues
7.3 Victoza (Liraglutide; Novo Nordisk): Revenue Forecast, 2017-2027
7.4 Byetta (Exenatide; AstraZeneca): Revenue Forecast, 2017-2027
7.5 Bydureon (Exenatide; AstraZeneca): Revenue Forecast, 2017-2027

8. Alpha-glucosidase Inhibitors Market, 2017-2027
8.1 Alpha-glucosidase Inhibitors Market, 2016
8.2 Alpha-glucosidase Inhibitors: Revenue Forecast, 2017-2027
8.2.1 Alpha-glucosidase Inhibitors: Market Trends, 2017-2027
8.2.1.1 Decline of Alpha-glucosidase Inhibitors Sales Due to Side Effects
8.2.1.2 Is a New Generation of Alpha-glucosidase Inhibitors Worthwhile?
8.3 Glucobay (Acarbose; Bayer AG): Revenue Forecast, 2017-2027
8.4 Basen (Voglibose; Takeda): Revenue Forecast, 2017-2027
8.5 Glyset (Miglitol; Pfizer): Revenue Forecast, 2017-2027

9. Meglitinides Market, 2017-2027
9.1 Meglitinides Market, 2016
9.2 Meglitinides: Revenue Forecast, 2017-2027
9.2.1 Meglitinides: Market Trends, 2017-2027
9.2.1.1 Combination Therapy: New Future for Meglitinides?
9.3 Prandin (Repaglinide; Novo Nordisk): Revenue Forecast, 2017-2027
9.4 Starlix (Nateglinide; Novartis): Revenue Forecast, 2017-2027
9.5 Glufast (Acarbose; Eisai): Revenue Forecast, 2017-2027

10. Thiazolidinediones Market, 2016

11. Sodium – glucose Co-transporter (SGLT2) Inhibitors Market, 2017-2027
11.1 SGLT2 Inhibitors Market, 2016
11.2 SGLT2 Revenue Forecast, 2017-2027
11.2.1 SGLT2 Market Trends, 2017-2027
11.3 Invokana (Canagliflozin; Johnson & Johnson): Revenue Forecast, 2017-2027
11.4 Forxiga (Dapagliflozin; AstraZeneca): Revenue Forecast, 2017-2027
11.5 Jardiance (Empagliflozin; Eli Lilly): Revenue Forecast, 2017-2027

12. Biguanides Market, 2017-2027
12.1 Biguanides Market, 2016
12.2 Biguanides: Revenue Forecast: 2017-2027
12.2.1 Biguanides: Market trends, 2017-2027
12.2.2 Metformin: Delay of Diabetes
12.2.3 Higher Mortality Associated with Combined Metformin and Insulin
12.3 Glucophage (Metformin; Merck (MSD)): Revenue Forecast, 2017-2027
12.4 Glumetza (Metformin Hydrochloride; Salix Pharmaceuticals): Revenue Forecast, 2017-2027
12.5 Fortamet (Metformin; Shionogi & Co): Revenue Forecast, 2017-2027

13. National Markets for Diabetes Drugs, 2017-2027
13.1 Leading National Markets for Diabetes Drugs, 2016
13.2 Leading National Diabetes Drugs Market: Revenue Forecast, 2017-2027
13.3 The US to Sustain its Market Leadership: Revenue Forecast 2017-2027
13.3.1 High Diabetes Prevalence within a Complex Healthcare System
13.4 The Japanese Market, Revenue Forecast, 2017-2027
13.4.1 Sanofi and Takeda Collaborate to Fight Diabetes in Japan
13.4.2 Novel Treatment Options in Japan
13.5 EU5 (Germany, France, UK, Italy, Spain) Market for Diabetes Drugs, 2016
13.5.1 The EU5 (Germany, France, UK, Italy, Spain) Market Revenue Forecasts, 2017-2027
13.5.2 Germany: Disease Treatment Measures Require Improvement – Revenue Forecast, 2017-2027
13.5.2.1 Tough Reimbursement Rules: More Data for Faster Approval?
13.5.3 French National Diabetes Market Revenue Forecast, 2017-2027
13.5.3.1 Great Standard of Care and Regulatory Reforms in France
13.5.4 The UK National Diabetes Market Revenue Forecast, 2017-2027
13.5.4.1 Faster Approvals for New Therapies in the UK
13.5.5 Italian National Diabetes Market Revenue Forecast, 2017-2027
13.5.6 Spanish National Diabetes Market Revenue Forecast, 2017-2027
13.6 China: The World’s Largest Diabetic Population – Revenue Forecast, 2017-2027
13.6.1 Presence of Multinational Companies and the Power of Buyers
13.6.2 Disparity in Regional Health Spending
13.6.3 Multi-Billion Dollar Investment to Improve Healthcare
13.7 The Indian Market: Revenue Forecast, 2017-2027
13.7.1 Focus on the Rural Population
13.8 The Russian National Diabetes Market, 2017-2027
13.8.1 High Out of Pocket Costs Reduce Compliance
13.9 Brazil: Improved Access to Care in Rural Areas – Revenue Forecast, 2017-2027
13.9.1 Localised Insulin Production in Brazil
13.9.2 Diabetes Awareness Initiatives Will Increase Market Potential

14. Diabetes Drug Market R&D Pipeline, 2016
14.1 New Diabetes Drugs Approvals and Leading Companies’ Developments, 2015-2016
14.1.1 Novo Nordisk
14.1.2 Eli Lilly & Boehringer Ingelheim
14.1.3 AstraZeneca
14.2 Human Insulins and Analogues: New Approvals
14.2.1 Insulin Glargine (Basaglar, Eli Lilly and Boehringer Ingelheim): Receives US Approval After Delays
14.2.2 Insulin Glargine (Toujeo, Sanofi): Will it Replace Lantus?
14.2.3 Afrezza (Sanofi and MannKind): The First Inhaled Insulin Fails to Make an Impact
14.3 Human Insulins and Analogues: Pipeline Developments: New Approvals
14.3.1 Tresiba (Novo Nordisk): Opportunity Revival
14.3.2 MK-1293 (Merck (MSD) and Biogen Idec): Will Provide more Biosimilar Competition for Lantus
14.3.3 NN9924 (Novo Nordisk)
14.3.4 BIOD-123 (Biodel)
14.4 DPP-4 Inhibitors: Pipeline Developments
14.4.1 Zafatek (Trelagliptin Succinate; Takeda and Furiex Pharmaceuticals): Approved in Japan
14.4.2 Omarigliptin (MK-3102; Merck (MSD))
14.5 GLP-1: New Approvals and Pipeline, 2016
14.5.1 Trulicity (Dulaglutide; Eli Lilly): Potential for Blockbuster Status
14.5.2 Semaglutide (NN9535; Novo Nordisk)
14.5.3 Xultophy (IdegLira; Novo Nordisk)
14.5.4 ITCA 650 (Intarcia Theraputics)
14.6 Sodium Glucose Co-Transporter 2: Pipeline Developments, 2016
14.6.1 Sotagliflozin (Lexicon Pharmacuticals)
14.6.2 Apleway (Tofogliflozin; Sanofi/Takeda)
14.6.3 MK8835 (Ertugliflozin; Merck (MSD))
14.6.4 Bexagliflozin (Theracos)
14.7 Other Diabetes Drugs: Pipeline Developments, 2016
14.7.1 DM199 (DiaMedica)
14.7.2 Glucokinase Activators
14.7.2.1 LY2608204 (Eli Lilly and Yabao Pharmaceutical Inc.)

15. Diabetes World Drug Market: SWOT and STEP Analysis
15.1 SWOT Analysis of the Diabetes Drug Market, 2017-2027
15.2 Strengths
15.2.1 Promising Research and Development
15.2.2 Secondary Indications
15.2.3 Biological Drugs are Tougher to copy and Offer Variety
15.2.4 Market Competition
15.3 Weaknesses
15.3.1 Lack of Disease Awareness
15.3.2 Tougher Reimbursement Rules
15.3.3 Increased Risk of Cardiovascular Complications
15.3.4 Rising Cost of Drug Development
15.4 Opportunities
15.4.1 Rising Disease Prevalence
15.4.2 Emerging National Markets Hold Great Potential
15.4.3 Novel Insulin Delivery Methods
15.4.4 New Classes of Anti-Diabetes Drugs
15.5 Threats
15.5.1 Type 1 Diabetes Vaccine
15.5.2 Increased Popularity of Other Therapies
15.5.3 Generic Drugs: Patent Expiries and Rising Competition
15.5.4 Regulatory Barriers – Challenges Getting Drug Approval
15.6 STEP Analysis of the World Diabetes Drugs Market, 2017-2027
15.6.1 Social Developments
15.6.2 Technological Advances
15.6.3 Economic Factors
15.6.4 Political Issues

16. Conclusions from the Research and Analysis
16.1 The Diabetes Market – Trends Shaping Those Treatments
16.2 Outlook of the Worlds Diabetes Drug Industry, 2017-2027
16.3 Insulin Will Continue to Dominate the Market
16.4 National Diabetes Market Outlooks, 2017-2027
16.5 Future Opportunities

Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Report Evaluation Form

List of Tables
Table 2.1 Types of Injectable Insulin, 2016
Table 2.2 Oral Drug Classes for Type 2 Diabetes, 2017
Table 2.3 Other Injectable Drugs for Type 2 Diabetes, 2016
Table 2.4 Combination Drug Therapies for Type 2 Diabetes, 2016
Table 3.1 World Diabetes Drugs Market: Revenue ($m) and Market Share (%) by Type of Medication, 2016
Table 3.2 World Diabetes Drugs Market: Sales ($m) and Market Share (%) by Drugs Class, 2016
Table 3.3 Top 10 Diabetes Drugs Sales ($m), 2016-2027
Table 3.4 World Diabetes Drugs Market: Revenue Forecasts ($m) by Drug Class, 2017-2027
Table 3.5 Injectable Diabetes Drugs: Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2017-2027
Table 3.6 Non-Injectable Diabetes Drugs: Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2017-2027
Table 4.1 Human Insulins and Analogues: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2016
Table 4.2 Leading Human Insulin and Analogue Drugs: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
Table 4.3 Top 3 Insulin Drug Producers: Insulin Portfolio, Sales ($m), and Insulin Submarket Share (%), 2016
Table 4.4 Lantus: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 4.5 NovoLog: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 4.6 Humalog: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 4.7 Levemir: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 4.8 Human Insulin: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 4.9 NovoMix: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 4.10 Humulin: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 5.1 DPP-4 Inhibitors: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2016
Table 5.2 Leading DPP-4 Inhibitor Drugs: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
Table 5.3 Januvia: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 5.4 Janumet: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 5.5 Galvus: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 5.6 Onglyza: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 5.7 Nesina: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 5.8 Tradjenta: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 6.1 Sulfonylureas: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2016
Table 6.2 Leading Sulfonylureas Drugs: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
Table 6.3 Diamicron: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 6.4 Amaryl: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 6.5 Glucotrol: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 7.1 GLP-1: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2016
Table 7.2 Leading GLP-1 Receptor Agonists: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
Table 7.3 Victoza: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 7.4 Byetta: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 7.5 Bydureon: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 8.1 Alpha-glucosidase Inhibitors: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2016
Table 8.2 Leading Alpha-glucosidase Inhibitors: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
Table 8.3 Glucobay: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 8.4 Basen: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 8.5 Glyset: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 9.1 Meglitinides: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2016
Table 9.2 Leading Meglitinides: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
Table 9.3 Prandin: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 9.4 Starlix: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 9.5 Glufast: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 10.1 Thiazolidinediones: Revenues ($m), 2016
Table 11.1 SGLT2 Inhibitors: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2016
Table 11.2 Leading SGLT2 Inhibitors: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
Table 11.3 Invokana: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 11.4 Forxiga: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 11.5 Jardiance: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 12.1 Biguanides: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2016
Table 12.2 Leading Biguanides: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
Table 12.3 Glucophage: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 12.4 Glumetza: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 12.5 Fortamet: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2027
Table 13.1 The Global Diabetes Drugs Market: Revenues ($m) and Market Shares (%) by Region, 2016
Table 13.2 Leading National Diabetes Drugs Markets: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
Table 13.3 The US: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2017-2027
Table 13.4 The Japan: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2017-2027
Table 13.5 EU5 (Germany, France, UK, Italy, Spain) Market: Revenue ($m), EU5 Market Share (%) and Global Market Share, 2016
Table 13.6 EU5 Diabetes Drugs Markets: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
Table 13.7 Germany: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2017-2027
Table 13.8 France: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2017-2027
Table 13.9 The UK: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2017-2027
Table 13.10 Italy: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2017-2027
Table 13.11 Spain: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2017-2027
Table 13.12 China: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2017-2027
Table 13.13 India: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2017-2027
Table 13.14 Russia: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2017-2027
Table 13.15 Brazil: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2017-2027
Table 14.1 FDA Approvals for Anti-Diabetes Drugs, 2015 and 2016

List of Figures
Figure 2.1 Diabetes Drugs Market Segmentation Overview, 2016
Figure 2.2 Diabetes Drugs Market Segmentation Overview, 2016
Figure 2.3 Diabetes Types and Classification, 2016
Figure 2.4 Causes of Diabetes, 2016
Figure 2.5 Prevalence of Diabetes in Leading Economic Countries, 2017
Figure 3.1 World Diabetes Drugs Market: Market Share (%) by Type of Medication, 2016
Figure 3.2 World Diabetes Drugs Market: Market Shares (%) by Drug Class, 2016
Figure 3.3 Top 10 Diabetes Drugs by Market Share (%), 2016
Figure 3.4 World Diabetes Drugs Market: Revenue Forecast ($m), 2017-2027
Figure 3.5 World Diabetes Drugs Market: AGR Forecast (%), 2017-2027
Figure 3.6 Injectable Diabetes Drugs: Revenue Forecast ($m), 2017-2027
Figure 3.7 Injectable Diabetes Drugs: AGR Forecast (%), 2017-2027
Figure 3.8 Non-Injectable Diabetes Drugs: Revenue Forecast ($m), 2017-2027
Figure 3.9 Non-Injectable Diabetes Drugs: AGR Forecast (%), 2017-2027
Figure 4.1 Human Insulins and Analogues: Market Shares (%) for Leading Drugs, 2016
Figure 4.2 Insulin and Insulin Analogues Market: Revenue Forecast ($m), 2017-2027
Figure 4.3 Insulin and Insulin Analogues Market: AGR Forecast (%), 2017-2027
Figure 4.4 Lantus: Drug Revenue Forecast ($m), 2017-2027
Figure 4.5 Lantus: AGR Forecast (%), 2017-2027
Figure 4.6 NovoLog: Drug Revenue Forecast ($m), 2017-2027
Figure 4.7 NovoLog: AGR Forecast (%), 2017-2027
Figure 4.8 Humalog: Drug Revenue Forecast ($m), 2017-2027
Figure 4.9 Humalog: AGR Forecast (%), 2017-2027
Figure 4.10 Levemir: Drug Revenue Forecast ($m), 2017-2027
Figure 4.11 Levemir: AGR Forecast (%), 2017-2027
Figure 4.12 Human Insulins: Drug Revenue Forecast ($m), 2017-2027
Figure 4.13 Human Insulins: AGR Forecast (%), 2017-2027
Figure 4.14 NovoMix: Drug Revenue Forecast ($m), 2017-2027
Figure 4.15 NovoMix: AGR Forecast (%), 2017-2027
Figure 4.16 Humulin: Drug Revenue Forecast ($m), 2017-2027
Figure 4.17 Humulin: AGR Forecast (%), 2017-2027
Figure 5.1 DPP-4 Inhibitors: Market Shares (%) for Leading Drugs, 2016
Figure 5.2 DPP-4 Inhibitors: Sales ($m) for Leading Drugs, 2016
Figure 5.3 DPP-4 Inhibitor Drugs Market: Revenue Forecast ($m), 2017-2027
Figure 5.4 DPP-4 Inhibitor Drugs Market: AGR Forecast (%), 2017-2027
Figure 5.5 Januvia: Drug Revenue Forecast ($m), 2017-2027
Figure 5.6 Januvia: AGR Forecast (%), 2017-2027
Figure 5.7 Janumet: Drug Revenue Forecast ($m), 2017-2027
Figure 5.8 Janumet: AGR Forecast (%), 2017-2027
Figure 5.9 Galvus: Drug Revenue Forecast ($m), 2017-2027
Figure 5.10 Galvus: AGR Forecast (%), 2017-2027
Figure 5.11 Onglyza: Drug Revenue Forecast ($m), 2017-2027
Figure 5.12 Onglyza: AGR Forecast (%), 2017-2027
Figure 5.13 Nesina: Drug Revenue Forecast ($m), 2017-2027
Figure 5.14 Nesina: AGR Forecast (%), 2017-2027
Figure 5.15 Tradjenta: Drug Revenue Forecast ($m), 2017-2027
Figure 5.16 Tradjenta: AGR Forecast (%), 2017-2027
Figure 6.1 Sulfonylureas: Market Shares (%) for Leading Drugs, 2016
Figure 6.2 Sulfonylureas: Sales ($m) for Leading Drugs, 2016
Figure 6.3 Sulfonylureas: Drug Revenue Forecast ($m), 2017-2027
Figure 6.4 Sulfonylureas: AGR Forecast (%), 2017-2027
Figure 6.5 Diamicron: Drug Revenue Forecast ($m), 2017-2027
Figure 6.6 Diamicron: AGR Forecast (%), 2017-2027
Figure 6.7 Amaryl: Drug Revenue Forecast ($m), 2017-2027
Figure 6.8 Amaryl: AGR Forecast (%), 2017-2027
Figure 6.9 Glucotrol: Drug Revenue Forecast ($m), 2017-2027
Figure 6.10 Glucotrol: AGR Forecast (%), 2017-2027
Figure 7.1 GLP-1: Market Shares (%) for Leading Drugs, 2016
Figure 7.2 GLP-1: Revenue ($m) for Leading Drugs, 2016
Figure 7.3 GLP-1 Receptor Agonists: Revenue Forecast ($m), 2017-2027
Figure 7.4 GLP-1 Receptor Agonists: AGR Forecast (%), 2017-2027
Figure 7.5 Victoza: Drug Revenue Forecast ($m), 2017-2027
Figure 7.6 Victoza: AGR Forecast (%), 2017-2027
Figure 7.7 Byetta: Drug Revenue Forecast ($m), 2017-2027
Figure 7.8 Byetta: AGR Forecast (%), 2017-2027
Figure 7.9 Bydureon: Drug Revenue Forecast ($m), 2017-2027
Figure 7.10 Bydureon: AGR Forecast (%), 2017-2027
Figure 8.1 Alpha-glucosidase Inhibitors: Market Shares (%) for Leading Drugs, 2016
Figure 8.2 Alpha-glucosidase Inhibitors: Revenue Sales ($m), 2016
Figure 8.3 Alpha-glucosidase Inhibitors: Revenue Forecast ($m), 2017-2027
Figure 8.4 Alpha-glucosidase Inhibitors: AGR Forecast (%), 2017-2027
Figure 8.5 Glucobay: Drug Revenue Forecast ($m), 2017-2027
Figure 8.6 Glucobay: AGR Forecast (%), 2017-2027
Figure 8.7 Basen: Drug Revenue Forecast ($m), 2017-2027
Figure 8.8 Basen: AGR Forecast (%), 2017-2027
Figure 8.9 Glyset: Drug Revenue Forecast ($m), 2017-2027
Figure 8.10 Glyset: AGR Forecast (%), 2017-2027
Figure 9.1 Meglitinides: Market Shares (%) for Leading Drugs, 2016
Figure 9.2 Meglitinides: Market Sales ($m) for Leading Drugs, 2016
Figure 9.3 Meglitinides: Revenue Forecast ($m), 2017-2027
Figure 9.4 Meglitinides: AGR Forecast (%), 2017-2027
Figure 9.5 Prandin: Drug Revenue Forecast ($m), 2017-2027
Figure 9.6 Prandin: AGR Forecast (%), 2017-2027
Figure 9.7 Starlix: Drug Revenue Forecast ($m), 2017-2027
Figure 9.8 Starlix: AGR Forecast (%), 2017-2027
Figure 9.9 Glufast: Drug Revenue Forecast ($m), 2017-2027
Figure 9.10 Glufast: AGR Forecast (%), 2017-2027
Figure 10.1 Thiazolidinediones: Revenues ($m), 2016
Figure 11.1 SGLT2 Inhibitors: Market Share (%) for Leading Drugs, 2016
Figure 11.2 SGLT2 Inhibitors: Sales ($m) for Leading Drugs, 2016
Figure 11.3 SGLT2 Inhibitors: Revenue Forecast ($m), 2017-2027
Figure 11.4 SGLT2 Inhibitors: AGR Forecast (%), 2017-2027
Figure 11.5 Invokana: Drug Revenue Forecast ($m), 2017-2027
Figure 11.6 Invokana: AGR Forecast (%), 2017-2027
Figure 11.7 Forxiga: Drug Revenue Forecast ($m), 2017-2027
Figure 11.8 Forxiga: AGR Forecast (%), 2017-2027
Figure 11.9 Jardiance: Drug Revenue Forecast ($m), 2017-2027
Figure 11.10 Jardiance: AGR Forecast (%), 2017-2027
Figure 12.1 Biguanides: Market Shares (%) for Leading Drugs, 2016
Figure 12.2 Biguanides: Revenue ($m) for Leading Drugs, 2016
Figure 12.3 Biguanides: Revenue Forecast ($m), 2017-2027
Figure 12.4 Biguanides: AGR Forecast (%), 2017-2027
Figure 12.5 Glucophage: Drug Revenue Forecast ($m), 2017-2027
Figure 12.6 Glucophage: AGR Forecast (%), 2017-2027
Figure 12.7 Glumetza: Drug Revenue Forecast ($m), 2017-2027
Figure 12.8 Glumetza: AGR Forecast (%), 2017-2027
Figure 12.9 Fortamet: Drug Revenue Forecast ($m), 2017-2027
Figure 12.10 Fortamet: AGR Forecast (%), 2017-2027
Figure 13.1 The Global Diabetes Drugs Market: Revenues ($m) by Region, 2016
Figure 13.2 The Global Diabetes Drugs Market: Market Shares (%) by Region, 2016
Figure 13.3 The US Diabetes Drugs Market: Revenue Forecast ($m), 2017-2027
Figure 13.4 The US Diabetes Drugs Market: AGR Forecast (%), 2017-2027
Figure 13.5 The Japanese Diabetes Drugs Market: Revenue Forecast ($m), 2017-2027
Figure 13.6 The Japanese Diabetes Drugs Market: AGR Forecast (%), 2017-2027
Figure 13.7 The EU5 (Germany, France, UK, Italy, Spain) Countries: Revenue ($m) by Country, 2016
Figure 13.8 EU5 (Germany, France, UK, Italy, Spain) Countries: EU5 Market Shares (%) by Country, 2016
Figure 13.9 EU5 (Germany, France, UK, Italy, Spain): Revenue Forecast ($m), 2017-2027
Figure 13.10 EU5 (Germany, France, UK, Italy, Spain): AGR Forecast (%), 2017-2027
Figure 13.11 EU5 (Germany, France, UK, Italy, Spain): Revenue Forecasts by Country ($m), 2017-2027
Figure 13.12 Germany: Revenue Forecast ($m), 2017-2027
Figure 13.13 Germany: AGR Forecast (%), 2017-2027
Figure 13.14 France: Revenue Forecast ($m), 2017-2027
Figure 13.15 France: AGR Forecast (%), 2017-2027
Figure 13.16 UK: Revenue Forecast ($m), 2017-2027
Figure 13.17 UK: AGR Forecast (%), 2017-2027
Figure 13.18 Italy: Revenue Forecast ($m), 2017-2027
Figure 13.19 Italy: AGR Forecast (%), 2017-2027
Figure 13.20 Spain: Revenue Forecast ($m), 2017-2027
Figure 13.21 Spain: AGR Forecast (%), 2017-2027
Figure 13.22 China: Revenue Forecast ($m), 2017-2027
Figure 13.23 China: AGR Forecast (%), 2017-2027
Figure 13.24 India: Revenue Forecast ($m), 2017-2027
Figure 13.25 India: AGR Forecast (%), 2017-2027
Figure 13.26 Russia: Revenue Forecast ($m), 2017-2027
Figure 13.27 Russia: AGR Forecast (%), 2017-2027
Figure 13.28 Brazil: Revenue Forecast ($m), 2017-2027
Figure 13.29 Brazil: AGR Forecast (%), 2017-2027
Figure 15.1 SWOT Analysis of the World Diabetes Drugs Market, 2017-2027
Figure 15.2 STEP Analysis of the World Diabetes Drugs Market, 2017-2027
Figure 17.1 Revenue for the Main Diabetes Drugs Classes ($m), 2016, 2021 and 2027
Figure 17.2 Revenue for the Main National Diabetes Markets ($m), 2016, 2021 and 2027

Actavis
Alphapharm
Amylin Pharmaceuticals (acquired by Bristol Myers Squibb)
Andromeda Biotech
Arisaph
Astellas Pharma
AstraZeneca
Bayer
Biocon
Blue Cross
Bristol-Myers Squibb
Biogen Idec
Boehringer Ingelheim
Boston Therapeutics
Chugai Pharmaceutical
Diabetes UK
DiaMedica
Diamyd Medical
Eisai
Eli Lilly
Express Scripts
Franco-Indian Pharmaceuticals
Furiex Pharmaceuticals
Genentech
Generex Biotechnology Corporation
GlaxoSmithKline (GSK)
Glenmark Pharmaceuticals
Google
Human Genome Sciences
Intarcia
Janssen (subsidiary of J&J)
Johnson & Johnson (J&J)
Lupin
Kissei Pharmaceuticals
Kotobuki Pharma
Kowa
MannKind Corporation
Mascot Health Series
Merck & Co.
Merck Serono
MSD KK (Asian subsidiary of Merck & Co.)
Mylan
Novartis
Novo Nordisk
Ono Pharmaceuticals
Oramed Pharmaceuticals
Patheon
Pfizer
Ranbaxy Laboratories
Roche
Salix Pharmaceuticals
Sandoz
Sanofi
Santarus (bought by Salix Pharmaceuticals)
Servier
Shantha Biotechnics (acquired by Sanofi)
Shionogi Pharmaceuticals
Shreya Life Sciences
Sun Pharma
Takeda
Taisho Pharmaceutical
Teva Pharmaceutical Industries
Theracos
Transdermal Specialities
Yabao Pharmaceutical
Zydus Cadila

Organizations Mentioned in the Report
American Diabetes Association
Associacao Nacional de Assistencia ao Diabetico (ANAD, Brazil)
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
International Diabetes Federation (IDF)
Ministry of Health (MoH, Germany)
Ministry of Health, Labour and Welfare (MHLW, Japan)
National Health Service (NHS, UK)
National Institute of Health and Clinical Excellence (NICE, UK)
Stanford University School of Medicine
World Health Organization (WHO)

Download sample pages

Complete the form below to download your free sample pages for Global Diabetes Drugs Market 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Global Diabetes Drugs Market 2017-2027


Do you have any custom requirements we can help you with?

Any specific country, geo region, market segment or specific company information?

Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

facebookWin a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.

Click here to ‘Like’ our Facebook page https://www.facebook.com/V.G.Pharma/

Would you like a free report overview of the report of your choice?

If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com

Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Would you like to get the latest Visiongain pharma reports catalogue?

What are the dynamic growth sectors? where are the regional business opportunities?

Which technologies will prevail and who are the leading companies succeeding in these sectors and why?

If you want definitive answers to business critical questions, discover Visiongain’s full range of business intelligence reports.

If so, please email Sara Peerun on sara.peerun@visiongain.com or call her today on +44 (0) 20 7549 9987

  • Human Microbiome Therapeutics Market 2019-2029
  • Top 20 Urology Companies 2019
  • Global Antidepressant and Anti-Anxiety Drugs Market Forecasts 2019-2029
  • The Top 100 In-Vitro Diagnostics Companies to Watch 2019
  • Global Hypertension Drugs Market 2019-2029
  • The Next Generation Sequencing Market 2019-2029
  • Lyophilisation for Pharmaceuticals: Products and Services 2019-2029
  • Top 25 In Vitro Diagnostics (IVD) Companies 2019
  • Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market 2019-2029
  • Global Biomarkets and Technologies Market 2019-2029
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Kuwait Pharmaceutical Association
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Generic Medicines Association
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia

Latest Pharma news

“Global Urology Devices market set to grow to $9.3bn by 2023” says new Visiongain report

The market is driven by a number of factors such as aging population, technological advancements, and increasing awareness programs.

21 May 2019

READ

“In Vitro Diagnostics (IVD) market set to grow to $91bn by 2024” says new Visiongain report

In recent years, the IVD market has experienced increased consolidation among industry participants, with significant merger and acquisition (M&A) activity, especially among larger companies as they diversify and manoeuvre for stronger positions.

14 May 2019

READ

“Indian Pharmaceutical market set to grow to $71bn by 2024” says new Visiongain report

Expected increases in the level of healthcare coverage will allow greater proportion of the population to be able to afford medical care, which is still mostly paid for out-of-pocket by patients, as a greater amount of people have health insurance to cover their medical expenses.

09 May 2019

READ

“Global mRNA Vaccines and Therapeutics market set to grow to $5.5bn by 2024” says new Visiongain

The major drivers supporting the growth of the mRNA Vaccines and Therapeutics Market are rising adoption of personalized medicine for effective treatment, advantages offered by mRNA-based products, and rising funding by pharmaceutical companies and government organizations.

07 May 2019

READ

Categories

Category